Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Sell
45
DNA Quote, Financials, Valuation and Earnings
Last price:
$9.35
Seasonality move
:
-43.67%
Day range:
$9.04 - $10.72
52-week range:
$5.26 - $74.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.21x
P/B ratio:
0.68x
Volume:
1.8M
Avg. volume:
1.6M
1-year change:
-86.49%
Market cap:
$543.8M
Revenue:
$251.5M
EPS (TTM):
-$12.99
Analysts' Opinion
-
Consensus RatingGinkgo Bioworks Holdings has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 1 Hold rating, and 1 Sell rating.
-
Price Target DownsideAccording to analysts' consensus price target of $37.00, Ginkgo Bioworks Holdings has an estimated downside of -13.32% from its current price of $9.46.
-
Price Target UpsideAccording to analysts, the highest upside price target is $120.00 representing -100% upside increase from its current price of $9.46.
Fair Value
-
According to the consensus of 3 analysts, Ginkgo Bioworks Holdings has -13.32% downside to fair value with a price target of $37.00 per share.
DNA vs. S&P 500
-
Over the past 5 trading days, Ginkgo Bioworks Holdings has underperformed the S&P 500 by -1.39% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Ginkgo Bioworks Holdings does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ginkgo Bioworks Holdings has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Ginkgo Bioworks Holdings reported revenues of $88.2M.
Earnings Growth
-
Ginkgo Bioworks Holdings has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Ginkgo Bioworks Holdings reported earnings per share of -$1.08.
Enterprise value:
-72.5M
EV / Invested capital:
-0.09x
Price / LTM sales:
2.21x
EV / EBIT:
--
EV / Revenue:
-0.33x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.19x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$175.6M
Return On Assets:
-38.86%
Net Income Margin (TTM):
-299.94%
Return On Equity:
-65.54%
Return On Invested Capital:
-65.54%
Operating Margin:
-60.2%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $527.9M | $315M | $217.1M | $55.4M | $88.2M | |
| Gross Profit | $287.3M | $237.4M | $175.6M | $48.5M | $76.2M | |
| Operating Income | -$3.7B | -$820.9M | -$567.2M | -$190.2M | -$53.1M | |
| EBITDA | -$3.6B | -$658.1M | -$630.6M | -$169.1M | -$35.9M | |
| Diluted EPS | -$91.60 | -$18.21 | -$12.99 | -$6.21 | -$1.08 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $1.8B | $1.5B | $1.1B | $662.5M | |
| Total Assets | -- | $2.2B | $1.9B | $2B | $1.5B | |
| Current Liabilities | -- | $90.3M | $124.8M | $168.5M | $114.4M | |
| Total Liabilities | -- | $532.6M | $431M | $773.7M | $682.9M | |
| Total Equity | -- | $1.6B | $1.4B | $1.3B | $797.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$313.2M | -$342.2M | -$335M | -$73.6M | -$103.5M | |
| Cash From Investing | -$92.9M | -$4.3M | -$95.8M | -$3.4M | -$10.2M | |
| Cash From Financing | -$13.5M | $95.2M | -$2.2M | -$315K | -$465K | |
| Free Cash Flow | -$344.9M | -$405.2M | -$387.3M | -$77.9M | -$118.6M | |
DNA
Sector
Market Cap
$543.8M
$18.8M
Price % of 52-Week High
12.78%
57.39%
Dividend Yield
0%
0%
Shareholder Yield
--
1.61%
1-Year Price Total Return
-86.49%
-18.92%
Beta (5-Year)
--
1.064
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$9.49
200-day SMA
Sell
Level
$18.24
Bollinger Bands (100)
Buy
Level
6.85 - 9.91
Chaikin Money Flow
Sell
Level
-341.5M
20-day SMA
Sell
Level
$9.62
Relative Strength Index (RSI14)
Buy
Level
51.80
ADX Line
Buy
Level
16.68
Williams %R
Neutral
Level
-70.3911
50-day SMA
Buy
Level
$8.58
MACD (12, 26)
Buy
Level
0.32
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Sell
Level
-217.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.8905)
Sell
CA Score
(Annual)
Level (-1.5351)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (3.16)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services.
Stock Forecast FAQ
In the current month, DNA has received 1 Buy ratings 1 Hold ratings, and 1 Sell ratings. The DNA average analyst price target in the past 3 months is $37.00.
-
Where Will Ginkgo Bioworks Holdings Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ginkgo Bioworks Holdings share price will drop to $37.00 per share over the next 12 months.
-
What Do Analysts Say About Ginkgo Bioworks Holdings?
Analysts are divided on their view about Ginkgo Bioworks Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ginkgo Bioworks Holdings is a Sell and believe this share price will rise from its current level to $7.00.
-
What Is Ginkgo Bioworks Holdings's Price Target?
The price target for Ginkgo Bioworks Holdings over the next 1-year time period is forecast to be $37.00 according to 3 Wall Street analysts, 1 of them rates the stock a Buy, 1 rates the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is DNA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ginkgo Bioworks Holdings is a Hold. 1 of 3 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of DNA?
You can purchase shares of Ginkgo Bioworks Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ginkgo Bioworks Holdings shares.
-
What Is The Ginkgo Bioworks Holdings Share Price Today?
Ginkgo Bioworks Holdings was last trading at $9.35 per share. This represents the most recent stock quote for Ginkgo Bioworks Holdings. Yesterday, Ginkgo Bioworks Holdings closed at $9.46 per share.
-
How To Buy Ginkgo Bioworks Holdings Stock Online?
In order to purchase Ginkgo Bioworks Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
52
TSLL alert for Dec 24
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
73
PSIX alert for Dec 24
Power Solutions International [PSIX] is up 27.42% over the past day.
Sell
31
SOXL alert for Dec 24
Direxion Daily Semiconductor Bull 3X Shares [SOXL] is up 11.87% over the past day.
